moxidectin and Ectoparasitic-Infestations

Ferrets (Mustela putorius furo) are becoming increasingly popular as pets and are kept in households with other pet animals such as dogs and cats, from which they may catch flea infestations with the predominant flea species Ctenocephalides felis. In this study, the efficacy of imidacloprid/moxidectin spot-on (Advocate/Advantage Multi) was investigated in the therapy and prevention of flea infestation in ferrets. Sixteen adult ferrets of varying weights and ages and of both sexes were included. Ferrets were infested with 50 fleas each on days -7, -1, 7, 14, 21, and 28. On study day -6, the animals were randomized into two groups based on body weight and flea count. Each ferret allocated to group 1 was treated with 0.4 ml of imidacloprid 10%/moxidectin 1% (Advocate/Advantage Multi). The ferrets in group 2 remained untreated. Flea counts were performed by combing 24 to 48 h after infestation. The primary efficacy criterion was the reduction in the number of fleas at each time point post treatment compared to the ferrets in the untreated control group. On day 1, the therapeutic efficacy was 100%. The preventative efficacy was 100% at 1 and 2 weeks post treatment, and it was >97% and >90% at 3 and 4 weeks post treatment. No local or systemic side effects were observed in any of the ferrets treated.

Topics: Administration, Topical; Animals; Drug Therapy, Combination; Ectoparasitic Infestations; Female; Ferrets; Imidazoles; Insecticides; Macrolides; Male; Neonicotinoids; Nitro Compounds; Siphonaptera

Topics: Administration, Topical; Animals; Cat Diseases; Cats; Dirofilaria immitis; Dirofilariasis; Drug Therapy, Combination; Ectoparasitic Infestations; Imidazoles; Insecticides; Macrolides; Neonicotinoids; Nitro Compounds; Siphonaptera; Treatment Outcome

Cercopithifilaria bainae is a tick-vectored filarioid nematode associated with erythematous dermatitis in dogs. It has not been reported previously in the United States.. To describe clinical, histological and parasitological diagnosis and treatment of C. bainae in a dog.. An 11-month-old golden retriever/standard poodle mixed breed dog from Florida (USA).. The dog had no travel history within or outside the United States, was presented with a one month history of annular erythematous plaques on the head and ulcers on the medial canthi. Lesions were unresponsive to antibiotic treatment.. Histopathological evaluation of skin biopsies revealed an eosinophilic to lymphohistiocytic perivascular dermatitis with multiple microgranulomas and rare 5-10 μm diameter microfilariae within microgranulomas. Microfilarial morphology was consistent with C. bainae. PCR and sequencing of 18S rRNA and mitochondrial cytochrome oxidase subunit I genes confirmed the nematodes as C. bainae. The dog was treated with a commercial spot-on containing imidacloprid and moxidectin, and clinical resolution occurred.. To the best of the authors' knowledge, this is the first report of C. bainae in a dog in the United States and the first description of dermatological lesions caused primarily by C. bainae.

Topics: Administration, Cutaneous; Animals; Antinematodal Agents; Disease Transmission, Infectious; Dog Diseases; Dogs; Drug Therapy, Combination; Ectoparasitic Infestations; Female; Filariasis; Filarioidea; Florida; Macrolides; Nematoda; Neonicotinoids; Nitro Compounds; Rhipicephalus sanguineus; Skin

Fluralaner provides efficacy against feline ectoparasites following topical administration. Moxidectin is routinely used to treat gastrointestinal nematode infections and prevent heartworm disease caused by Dirofilaria immitis. Praziquantel is routinely used to treat feline tapeworm infections. The safety of a fluralaner plus moxidectin combination topical solution (Bravecto™ Plus, MSD Animal Health) was assessed when administered concurrently with a commercially available praziquantel topical solution (Droncit™ Spot-on, Bayer Animal Health GmbH). The highest dose rates in clinical use were tested.. Concurrent topical administration of a fluralaner plus moxidectin and a praziquantel product did not result in adverse findings. One out of ten cats receiving praziquantel only (control group), and two out of ten cats receiving fluralaner plus moxidectin and praziquantel (treatment group) had dandruff-like flakes in their coat at the application site. Two out of the ten control cats and three cats out of the ten treatment group cats had very small amounts of unidentified material (minute crusts or crumbs) at the application site which was only visible during close inspection.. The concurrent treatment of cats with fluralaner plus moxidectin and praziquantel at the maximum dose in clinical use was well tolerated.

Topics: Acaricides; Administration, Topical; Animals; Anthelmintics; Cat Diseases; Cats; Dirofilariasis; Drug Therapy, Combination; Ectoparasitic Infestations; Female; Insecticides; Isoxazoles; Macrolides; Male; Nematode Infections; Praziquantel; Random Allocation; Treatment Outcome

The recent resurgence of the common bed bug Cimex lectularius L. throughout western industrialized nations has been facilitated in part by the insect becoming pesticide-resistant. Novel control strategies, including xenointoxication, should be considered to combat C. lectularius. Ivermectin, a U.S. Food and Drug Administration (FDA)-approved treatment for several human parasites, and the antiparasitic drug moxidectin, currently being explored in human clinical trials, were evaluated for efficacy against C. lectularius. Results showed that C. lectularius fed on ivermectin or moxidectin blood concentrations of >25 ng/mL and had significantly higher mortality (50-100 %) than controls (0-6 %) by day 13. Bed bugs that survived a blood meal containing >2.5 ng/mL of ivermectin suffered long-term sequelae including reduced fecundity, feeding difficulty, and incomplete ecdysis. Some insects that survived a blood meal containing ≤75 ng/mL moxidectin were able to feed and reproduce.

Topics: Animals; Bedbugs; Drug Resistance; Ectoparasitic Infestations; Humans; Insecticides; Ivermectin; Macrolides

A 3-year study was performed in southern Alberta, Canada to assess the effect of endectocide residues on the attractiveness of cattle dung to colonizing insects. In 2003 and 2004, insect captures were compared between pitfall traps baited with dung of untreated cattle and paired traps baited with dung of cattle that had been treated 7 days previously with topically applied doramectin, eprinomectin, ivermectin or moxidectin. Faecal residues associated with each compound affected insect captures in both spring and autumn of each year. Effects were detected (P < 0.05) for a total of 94 cases representing 27 insect taxa from 13 families in three orders (Coleoptera, Diptera, Hymenoptera). Two-fold differences in captures were common. Up to six-fold differences were observed. Eleven cases of attraction and 11 cases of repellency were associated with residues of doramectin. Eprinomectin tended to repel insects, with decreased captures for 19 of 29 cases of effect. Ivermectin showed a strong attractive effect, with increased captures for 17 of 25 cases. Moxidectin also showed a strong attractive effect, with increased captures for 17 of 18 cases. Comparisons between compounds suggested that results for doramectin best predicted results for eprinomectin and vice versa. In 2005, insect captures were compared between pitfall traps baited with dung of untreated cattle and traps baited with dung from cattle treated 3, 7 or 14 days previously with topically applied doramectin. Effects were detected in 14 cases plus one case of near significance (P= 0.053). Significant differences between control vs. days 3, 7 and/or 14 dung were detected in nine cases. Residues enhanced captures in seven of these cases. Day 14 dung affected captures in six of these cases. This study shows that endectocide residues can affect the number of insects attracted to colonize and oviposit in dung. Hence, the emergence of their offspring from field-colonized dung of untreated vs. endectocide-treated cattle should not be used as a measure of residue toxicity per se, but rather as a measure of 'insect activity'. Insect activity is a composite measure of residue toxicity, the number and species composition of insect colonists, and the mortality factors (e.g. predation, parasitism, competition) associated with the co-occurrence of these species in the dung pat.

Topics: Administration, Topical; Alberta; Animals; Cattle; Cattle Diseases; Ectoparasitic Infestations; Feces; Insecta; Insecticides; Ivermectin; Macrolides; Male; Oviposition; Pesticide Residues; Random Allocation; Time Factors

Sixteen controlled laboratory studies, involving 420 kittens and cats, were conducted to evaluate the efficacy and safety of topically applied formulations of imidacloprid and moxidectin for the prevention of feline heartworm disease, treatment of flea infestations and treatment and control of intestinal nematodes. Unit-dose applicators and the dosing schedule used in these studies were designed to provide a minimum of 10mg imidacloprid and 1mg moxidectin/kg. Treatments were applied topically by parting the hair at the base of the skull and applying the solution on the skin. Imidacloprid treatment alone did not display activity against Dirofilaria immitis or intestinal nematodes and moxidectin treatment alone provided little or no activity against adult Ctenocephalides felis infestations. The formulation containing 10% imidacloprid and 1% moxidectin was 100% efficacious against the development of adult D. immitis infections when cats were treated 30 days after inoculation with third-stage larvae. A single treatment with this formulation also provided 88.4-100% control of adult C. felis for 35 days. Imidacloprid/moxidectin was 100% efficacious against adult Toxocara cati and 91.0-98.3% efficacious against immature adults and fourth-stage T. cati larvae. The formulation provided 98.8-100% efficacy against adult Ancylostoma and immature adults and third-stage A. tubaeforme larvae. Monthly topical application with 10% imidacloprid/1% moxidectin is convenient, efficacious and safe for the prevention of feline heartworm disease, treatment of flea infestation and for the treatment and control of intestinal nematode infections of cats.

Topics: Administration, Topical; Animals; Antinematodal Agents; Cat Diseases; Cats; Dirofilariasis; Dose-Response Relationship, Drug; Drug Administration Schedule; Ectoparasitic Infestations; Female; Filaricides; Imidazoles; Insecticides; Intestinal Diseases, Parasitic; Life Cycle Stages; Macrolides; Male; Nematode Infections; Neonicotinoids; Nitro Compounds; Treatment Outcome

A study was conducted to determine the safety of the dermal application of 10% imidacloprid/2.5% moxidectin topical solution in ivermectin-sensitive collies. Each milliliter of this solution contains 100mg of imidacloprid and 25mg of moxidectin. A total of 21 collies were prescreened for ivermectin-sensitivity and heartworm negative status prior to selection for the study. Animals were assigned based on the maximum ivermectin-sensitivity score demonstrated during the prestudy screening. Treatment groups included a 3x and 5x test article group, and a 3x and 5x mineral oil control group. The 3x and 5x doses were administered at three and five times, respectively, the 1x dose based on the animal's body weight. On day 0, 3 of the 21 dogs were treated with dermal applications of a preliminary dose of 3x test article to screen for unexpected signs of toxicity with the remaining 18 dogs being treated with 3x mineral oil to blind for the volume of liquid applied. After no signs of toxicity were observed, these same three dogs were treated with 3x of test article and 2x mineral oil on days 28 and 56. The remaining 18 animals were equally allocated to either a 5x test article group or a 5x control group and were each treated on days 28, 56, and 84. Personnel performing observations were blinded to treatment. Observations were made for clinical signs of ivermectin sensitivity twice daily during non-dosing days. On treatment days, dogs were observed hourly for the first 4h post-treatment and at 6, 8, 12, 18 and 24h. Signs of toxicosis were not observed in any of the dogs throughout the observation period. This study demonstrated the safety of imidacloprid/moxidectin, when administered to collies testing positive for ivermectin sensitivity at dosages up to five times the maximum recommended dose.

Topics: Administration, Topical; Animals; Dog Diseases; Dogs; Ectoparasitic Infestations; Female; Imidazoles; Insecticides; Macrolides; Male; Neonicotinoids; Nitro Compounds; Plants; Random Allocation; Siphonaptera; Skin Diseases; Solutions

Four trials, three in the United States and one in South Africa, were conducted to evaluate the potential value of a novel self-medicating applicator in the passive control of gastrointestinal nematodes in cattle and deer, and of files and ticks on cattle using oil-based treatments. The results of the trials demonstrated that this applicator is an effective and practical device for the passive treatment of both deer and cattle for trichostrongyle infections using the endectocide, moxidectin (Cydectin. Fort Dodge Animal Health, USA), of cattle for hom fly (Haemotobia irritans) infestations using the insecticide, cyfluthrin (CyLence, Bayer AG, Germany) and of cattle for tick infestations (in particular Amblyomma hebraeum and Rhipicephalus appendiculatus) using the acaricides deltamethrin and amitraz (Delete All, Intervet, South Africa).

Topics: Administration, Topical; Animals; Animals, Domestic; Animals, Wild; Anthelmintics; Cattle; Deer; Drug Combinations; Ectoparasitic Infestations; Female; Insecticides; Intestinal Diseases, Parasitic; Macrolides; Male; Nematode Infections; Nitriles; Pesticide Synergists; Piperonyl Butoxide; Pyrethrins; Random Allocation; Tick Control; Tick Infestations; Toluidines

Bioassays were conducted to study the effect of a single therapeutic dose of injectable ivermectin, doramectin or moxidectin given to cattle and pigs and excreted in their faeces, against larvae of the housefly, Musca domestica L. (Diptera: Muscidae). Five cattle were treated with each of the test products. Cattle faecal samples were collected before treatment and on days 1, 2, 3, 6, 10, 16, 20, 23 and 28 after treatment. Three groups of pigs, each comprising 12-14 pregnant sows and gilts, were used in the experiment. Pig faeces was collected from each group before treatment and on days 1, 3, 5, 7, 9, 11, 13, 15 and 20 after treatment. Thirty, first-stage larvae were placed into 100 g of faeces. Five replicates were examined for each time-point and for each endectocide group. Evaluation was based on the number of larvae surviving to adult emergence. Low numbers of adults emerged from samples taken from cattle 1 day after treatment, indicating that ivermectin and doramectin were rapidly excreted in the faeces and affected the development of the house fly. A larvicidal effect of both drugs in cattle faeces was present for a period of about 3-4 weeks and lasted a few days longer in cattle treated with doramectin than with ivermectin. In cattle, the larvicidal activity of moxidectin was first observed in faecal samples collected 2 days post-treatment; however, it killed fewer larvae than the other two drugs. The larvicidal effect of moxidectin subsequently decreased. Ivermectin and doramectin exhibited a pronounced larvicidal effect against the house fly in the faeces of pigs. The effect of doramectin was of longer duration. Moxidectin gave the weakest larvicidal effect in pig faeces. The main difference between the results obtained for the two livestock species is that peak toxicity occurred relatively later and for a shorter duration in pig than in cattle faeces.

Topics: Animals; Cattle; Cattle Diseases; Ectoparasitic Infestations; Feces; Houseflies; Insecticides; Ivermectin; Larva; Macrolides; Swine; Swine Diseases

Cattle were treated with topical formulations of endectocides to assess the larvicidal activity of faecal residues against horn fly, Haematobia irritans (L.), house fly, Musca domestica L., and stable fly, Stomoxys calcitrans (L.) (Diptera: Muscidae). In laboratory bioassays, doramectin, eprinomectin and ivermectin suppressed horn fly in dung of cattle treated at least 4 weeks previously and suppressed house fly and stable fly in dung of cattle treated 1-5 weeks previously. Moxidectin suppressed horn fly in dung from cattle treated no more than one week previously and did not suppress house fly and stable fly. Results combined for the three species across two experiments suggested that, ranked in descending order of larvicidal activity, doramectin > ivermectin approximately = eprinomectin >> moxidectin.

Topics: Animals; Anti-Bacterial Agents; Antinematodal Agents; Cattle; Cattle Diseases; Diptera; Ectoparasitic Infestations; Feces; Insecticides; Ivermectin; Larva; Macrolides; Nematode Infections

Slow release formulations of 375, 750, and 1,125 mg (AI) in 50-g boluses and a subcutaneous injectable formulation (0.2 mg AI/kg body wt) of moxidectin (CL301423) were tested for the control of the little blue cattle louse, Solenoptes capillatus (Enderlein), and the cattle biting louse, Bovicola bovis (L). S. capillatus populations were reduced 4 wk after treatment and complete control was observed 6 wk after treatment in groups treated with boluses, B. bovis were first observed at 3 wk and continued to increase throughout the 14-wk test period. These were experimental boluses and future boluses may perform differently. Subcutaneous injections of moxidectin gave complete control of S. capillatus for a 27-d test period. Feces from animals treated with boluses were tested with face fly larvae, Musca autumnalis De Geer, to demonstrate fecal activity of moxidectin. Larval mortality in these groups ranged from 90 to 30% from 2 d to 10 wk after treatment.

Topics: Animals; Anoplura; Anthelmintics; Anti-Bacterial Agents; Cattle; Cattle Diseases; Ectoparasitic Infestations; Female; Lice Infestations; Macrolides; Male; Muscidae; Phthiraptera